Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy

Kun Huei Yeh, Chia Tung Shun, Chi Long Chen, Jaw Town Lin, Wei Jei Lee, Po Huang Lee, Yao Chang Chen, Ann Lii Cheng

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Recent in vitro evidence has strongly suggested that most anti-cancer drugs exert their cytotoxic effects via a p53-dependent apoptosis pathway. An intact p53 molecule appears to be a prerequisite for the cancer cells to be susceptible to these drugs. In this study, we specifically examined if overexpression of p53 may confer drug resistance on human gastric cancer. METHODOLOGY: All patients were treated by an empirical HDFL regimen (weekly 24-hour infusion of 5-FU, 2600 mg/m2 and leucovorin, 300 mg/m2) in a prospective phase II clinical trial. Among them, patients with adequate pre-chemotherapy gastric cancer tissues for immunohistochemical studies were selected for this study. A p53 DO7 monoclonal antibody was used to detect the overexpression of p53. The results were designated as '-' or '+' by the independent interpretation of two pathologists. RESULTS: A total of 30 patients, 18 men and 12 women, with a median age of 61.5 years (range: 32-78 years), were studied. There were 15 responders and 15 non-responders to HDFL chemotherapy. The percentage of p53 overexpression with positive DO7 staining was 20.0% (6 out of 30). There were no significant differences in the pertinent clinicopathologic features between the patients with positive staining of p53 and the patients with negative staining of p53. Three out of 6 (50.0%) patients with positive staining of p53 and 12 out of 24 (50.0%) patients with negative staining of p53 responded to chemotherapy, respectively (p = 1.000 by Fisher's exact test). CONCLUSIONS: Our data suggested that the overexpression of p53 does not predict drug resistance to 5-FU of human gastric cancer.

Original languageEnglish
Pages (from-to)610-615
Number of pages6
JournalHepato-Gastroenterology
Volume46
Issue number25
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Drug Resistance
Fluorouracil
Stomach Neoplasms
Drug Therapy
Negative Staining
Staining and Labeling
Phase II Clinical Trials
Leucovorin
Pharmaceutical Preparations
Neoplasms
Monoclonal Antibodies
Apoptosis

Keywords

  • 5-FU
  • Drug resistance
  • Gastric cancer
  • p53 overexpression

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. / Yeh, Kun Huei; Shun, Chia Tung; Chen, Chi Long; Lin, Jaw Town; Lee, Wei Jei; Lee, Po Huang; Chen, Yao Chang; Cheng, Ann Lii.

In: Hepato-Gastroenterology, Vol. 46, No. 25, 1999, p. 610-615.

Research output: Contribution to journalArticle

Yeh, KH, Shun, CT, Chen, CL, Lin, JT, Lee, WJ, Lee, PH, Chen, YC & Cheng, AL 1999, 'Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy', Hepato-Gastroenterology, vol. 46, no. 25, pp. 610-615.
Yeh, Kun Huei ; Shun, Chia Tung ; Chen, Chi Long ; Lin, Jaw Town ; Lee, Wei Jei ; Lee, Po Huang ; Chen, Yao Chang ; Cheng, Ann Lii. / Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. In: Hepato-Gastroenterology. 1999 ; Vol. 46, No. 25. pp. 610-615.
@article{36ffacddbd394b6f8510334b5a317d1d,
title = "Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy",
abstract = "BACKGROUND/AIMS: Recent in vitro evidence has strongly suggested that most anti-cancer drugs exert their cytotoxic effects via a p53-dependent apoptosis pathway. An intact p53 molecule appears to be a prerequisite for the cancer cells to be susceptible to these drugs. In this study, we specifically examined if overexpression of p53 may confer drug resistance on human gastric cancer. METHODOLOGY: All patients were treated by an empirical HDFL regimen (weekly 24-hour infusion of 5-FU, 2600 mg/m2 and leucovorin, 300 mg/m2) in a prospective phase II clinical trial. Among them, patients with adequate pre-chemotherapy gastric cancer tissues for immunohistochemical studies were selected for this study. A p53 DO7 monoclonal antibody was used to detect the overexpression of p53. The results were designated as '-' or '+' by the independent interpretation of two pathologists. RESULTS: A total of 30 patients, 18 men and 12 women, with a median age of 61.5 years (range: 32-78 years), were studied. There were 15 responders and 15 non-responders to HDFL chemotherapy. The percentage of p53 overexpression with positive DO7 staining was 20.0{\%} (6 out of 30). There were no significant differences in the pertinent clinicopathologic features between the patients with positive staining of p53 and the patients with negative staining of p53. Three out of 6 (50.0{\%}) patients with positive staining of p53 and 12 out of 24 (50.0{\%}) patients with negative staining of p53 responded to chemotherapy, respectively (p = 1.000 by Fisher's exact test). CONCLUSIONS: Our data suggested that the overexpression of p53 does not predict drug resistance to 5-FU of human gastric cancer.",
keywords = "5-FU, Drug resistance, Gastric cancer, p53 overexpression",
author = "Yeh, {Kun Huei} and Shun, {Chia Tung} and Chen, {Chi Long} and Lin, {Jaw Town} and Lee, {Wei Jei} and Lee, {Po Huang} and Chen, {Yao Chang} and Cheng, {Ann Lii}",
year = "1999",
language = "English",
volume = "46",
pages = "610--615",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "25",

}

TY - JOUR

T1 - Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy

AU - Yeh, Kun Huei

AU - Shun, Chia Tung

AU - Chen, Chi Long

AU - Lin, Jaw Town

AU - Lee, Wei Jei

AU - Lee, Po Huang

AU - Chen, Yao Chang

AU - Cheng, Ann Lii

PY - 1999

Y1 - 1999

N2 - BACKGROUND/AIMS: Recent in vitro evidence has strongly suggested that most anti-cancer drugs exert their cytotoxic effects via a p53-dependent apoptosis pathway. An intact p53 molecule appears to be a prerequisite for the cancer cells to be susceptible to these drugs. In this study, we specifically examined if overexpression of p53 may confer drug resistance on human gastric cancer. METHODOLOGY: All patients were treated by an empirical HDFL regimen (weekly 24-hour infusion of 5-FU, 2600 mg/m2 and leucovorin, 300 mg/m2) in a prospective phase II clinical trial. Among them, patients with adequate pre-chemotherapy gastric cancer tissues for immunohistochemical studies were selected for this study. A p53 DO7 monoclonal antibody was used to detect the overexpression of p53. The results were designated as '-' or '+' by the independent interpretation of two pathologists. RESULTS: A total of 30 patients, 18 men and 12 women, with a median age of 61.5 years (range: 32-78 years), were studied. There were 15 responders and 15 non-responders to HDFL chemotherapy. The percentage of p53 overexpression with positive DO7 staining was 20.0% (6 out of 30). There were no significant differences in the pertinent clinicopathologic features between the patients with positive staining of p53 and the patients with negative staining of p53. Three out of 6 (50.0%) patients with positive staining of p53 and 12 out of 24 (50.0%) patients with negative staining of p53 responded to chemotherapy, respectively (p = 1.000 by Fisher's exact test). CONCLUSIONS: Our data suggested that the overexpression of p53 does not predict drug resistance to 5-FU of human gastric cancer.

AB - BACKGROUND/AIMS: Recent in vitro evidence has strongly suggested that most anti-cancer drugs exert their cytotoxic effects via a p53-dependent apoptosis pathway. An intact p53 molecule appears to be a prerequisite for the cancer cells to be susceptible to these drugs. In this study, we specifically examined if overexpression of p53 may confer drug resistance on human gastric cancer. METHODOLOGY: All patients were treated by an empirical HDFL regimen (weekly 24-hour infusion of 5-FU, 2600 mg/m2 and leucovorin, 300 mg/m2) in a prospective phase II clinical trial. Among them, patients with adequate pre-chemotherapy gastric cancer tissues for immunohistochemical studies were selected for this study. A p53 DO7 monoclonal antibody was used to detect the overexpression of p53. The results were designated as '-' or '+' by the independent interpretation of two pathologists. RESULTS: A total of 30 patients, 18 men and 12 women, with a median age of 61.5 years (range: 32-78 years), were studied. There were 15 responders and 15 non-responders to HDFL chemotherapy. The percentage of p53 overexpression with positive DO7 staining was 20.0% (6 out of 30). There were no significant differences in the pertinent clinicopathologic features between the patients with positive staining of p53 and the patients with negative staining of p53. Three out of 6 (50.0%) patients with positive staining of p53 and 12 out of 24 (50.0%) patients with negative staining of p53 responded to chemotherapy, respectively (p = 1.000 by Fisher's exact test). CONCLUSIONS: Our data suggested that the overexpression of p53 does not predict drug resistance to 5-FU of human gastric cancer.

KW - 5-FU

KW - Drug resistance

KW - Gastric cancer

KW - p53 overexpression

UR - http://www.scopus.com/inward/record.url?scp=0033039159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033039159&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 610

EP - 615

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 25

ER -